These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11814334)

  • 1. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
    Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
    Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.
    Laco GS
    PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
    Streltsov SA
    J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
    Laco GS; Du W; Kohlhagen G; Sayer JM; Jerina DM; Burke TG; Curran DP; Pommier Y
    Bioorg Med Chem; 2004 Oct; 12(19):5225-35. PubMed ID: 15351405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
    Xiao X; Cushman M
    J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
    Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
    Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
    J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
    Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
    Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
    Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
    J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
    Xiao X; Cushman M
    J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.
    Lauria A; Ippolito M; Almerico AM
    J Mol Model; 2007 Mar; 13(3):393-400. PubMed ID: 17072654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA.
    Choi I; Kim C; Choi S
    Arch Pharm Res; 2007 Dec; 30(12):1526-35. PubMed ID: 18254239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification.
    Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM
    Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
    Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
    Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
    Kerrigan JE; Pilch DS
    Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
    Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
    J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
    Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
    Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.